Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Mircera Clears FDA, But U.S. Launch Appears Stalled

Executive Summary

FDA approved Roche's long-acting erythropoiesis-stimulating agent Mircera for the treatment of anemia associated with chronic renal failure in adults Nov. 14, but a near-term launch of the product appears unlikely given Amgen's legal hold on the market

You may also be interested in...



Year In Review: New Biologics Total Seven In 2007, But Only Four Will See Market

FDA approved only one biologic with mass-market potential in 2007, a seasonal flu vaccine. Nearly half of the new biologics approved - three of seven - will not be available commercially. Another three are for orphan indications

Year In Review: New Biologics Total Seven In 2007, But Only Four Will See Market

FDA approved only one biologic with mass-market potential in 2007, a seasonal flu vaccine. Nearly half of the new biologics approved - three of seven - will not be available commercially. Another three are for orphan indications

FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count

Three-quarters of the new molecular entities cleared by FDA in 2007 were approved on the first review cycle, a high for this decade and a positive note to counterbalance the record low number of NMEs approved

Related Content

UsernamePublicRestriction

Register

PS049031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel